Personalized medicine for patients with MDR-TB. (Q38617675)

4 September 2017

title

Personalized medicine for patients with MDR-TB. (English)

1 reference

4 September 2017

main subject

personalized medicine

1 reference

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26507429%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26507429%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

Jan Heyckendorf

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26507429%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

language of work or name

English

0 references

publication date

27 October 2015

1 reference

Journal of Antimicrobial Chemotherapy

4 September 2017

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26507429%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

volume

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26507429%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

issue

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26507429%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

page(s)

852-855

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26507429%20AND%20SRC:MED&resulttype=core&format=json

Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010

5 June 2020

cites work

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV354

Successful '9-month Bangladesh regimen' for multidrug-resistant tuberculosis among over 500 consecutive patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV354

Short, highly effective, and inexpensive standardized treatment of multidrug-resistant tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV354

Multidrug-resistant tuberculosis in Europe, 2010-2011

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV354

Availability, price and affordability of anti-tuberculosis drugs in Europe: a TBNET survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV354

Getting personal perspectives on individualized treatment duration in multidrug-resistant and extensively drug-resistant tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV354

Rapid molecular detection of tuberculosis and rifampin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV354

Recent trends in euthanasia and other end-of-life practices in Belgium

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV354

Evaluation of the GenoType MTBDRplus assay for rifampin and isoniazid susceptibility testing of Mycobacterium tuberculosis strains and clinical specimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV354

Feasibility of the GenoType MTBDRsl assay for fluoroquinolone, amikacin-capreomycin, and ethambutol resistance testing of Mycobacterium tuberculosis strains and clinical specimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV354

Whole-genome sequencing for prediction of Mycobacterium tuberculosis drug susceptibility and resistance: a retrospective cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV354

Rapid Whole-Genome Sequencing of Mycobacterium tuberculosis Isolates Directly from Clinical Samples

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV354

Evaluation of moxifloxacin for the treatment of tuberculosis: 3 years of experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV354

Serum drug concentrations predictive of pulmonary tuberculosis outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV354

Therapeutic drug monitoring in the treatment of tuberculosis: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV354

Dried Blood Spots: A New Tool for Tuberculosis Treatment Optimization

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV354

Population pharmacokinetics and limited sampling strategy for first-line tuberculosis drugs and moxifloxacin

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV354

Advancing host-directed therapy for tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV354

The role of genetic polymorphisms in cytochrome P450 and effects of tuberculosis co-treatment on the predictive value of CYP2B6 SNPs and on efavirenz plasma levels in adult HIV patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV354

Genetics of congenital and drug-induced long QT syndromes: current evidence and future research perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV354